PDX Model Studies

We currently have more than 400 fully characterized proprietary patient-derived xenografts in our portfolio, which represent all major histotypes and tumors, and provide extensive background and characterization.

In PDX models tumor tissue is extracted from a donor patient and implanted into immunocompromised mice, to screen therapies.
Figure 1: Schematic of Patient Derived Xenograft (PDX) Models

Our PDX Model portfolio includes:

  • Subcutaneous, orthotopic, and disseminated models of cancer
  • Extensive molecular and pharmacological characterization, and complete records on patients‘ pretreatment
  • Integrated approach using the same PDX models and/or the corresponding cell line
  • 2D/3D screening assays and subsequent PDX in vivo efficacy studies
  • Identification of biomarkers, which predicts tumor sensitivity of compounds
  • PDX Model platform using humanized mice in standard or single mouse trial format (SMT)

Constant addition of new PDX models, which are continuously established through international collaborations with major hospitals and universities.

Patient-Derived Xenografts - Tumor Model Compendium
cancer cell

Support your in vitro, in vivo, and ex vivo studies with the following at your fingertips:

  • New user-friendly search and easy-to-navigate menus
  • New model data, including HLA typing, growth curves, and tumor images
  • New multi-parameter search options for all tumor model types

Visit our Compendium

Patient-Derived Xenografts

Charles River’s patient-derived xenografts use tumor grafts as explants established as models at low passage numbers (average of six passes removed from patient). They have not been grown in plastic or propagated as cell cultures.

Establishing xenograft tumor models from patient-derived tumor tissue (PDTT) at low passage is believed to conserve original tumor characteristics such as heterogeneous histology, clinical biomolecular signature, malignant phenotypes and genotypes, tumor architecture, and tumor vasculature. Based on this prevalent hypothesis, patient-derived xenografts are believed to offer relevant predictive insights into clinical outcomes when evaluating the efficacy of novel cancer therapies.

By leveraging the wealth of information that we have on each tumor model, we can help you with your study and provide suggested patient-derived xenograft PDX models to test.



Leveraging In vitro and Ex Vivo PDX Models

2D and 3D cell-based assays performed with low passage, PDX-derived material serve as cost- and time-effective tools for selecting appropriate PDX models as well as conditions for in vivo efficacy studies. An integrated approach based on PDX in vitro, ex vivo, in vivo, and bioinformatics data will facilitate drug development and enhance the speed of preclinical oncology research.

Pharmacological effects and pharmacokinetics of test compounds can be determined in the tumor microenvironment with high sensitivity and temporal resolution by our in vivo microdialysis services.

Scientific Reports logo

A High-Content Image Analysis Approach for Quantitative Measurements of Chemosensitivity in Patient-Derived Tumor Microtissues

Learn about the data correlation between in vitro 3D PDX cultures and in vivo PDX tumor models. Read Article

To learn more about our offerings, including molecular information, visit our Tumor Model Compendium.


Frequently Asked Questions (FAQs) in Oncology Research

Have another question or need advice on which model is right for you?

Ask our Experts


Bioinformatics: Leveraging the Molecular Landscape to Drive Oncology Discovery

Oct. 23, 2019 | Online Webinar
Reserve your Seat

Harnessing The Entire Immune System

Oct. 24-25th, 2019 | Cambridge, MA
Learn More